Thursday, October 22, 2026

Stock Valuations

1 article

Ambiq Micro's 20x P/S Ratio Signals Compression Risk as Net Losses Hit $38.35M

Ambiq Micro trades at a 20x price-to-sales ratio while reporting a net income of -$38.35M, creating a fragile valuation structure dependent on uninterrupted hypergrowth. Any revenue deceleration or margin deterioration could trigger swift multiple compression. The ultra-low-power semiconductor specialist operates in high-growth edge AI and IoT markets, but premium valuations leave investors with little margin for execution error.

LM Salvado•May 24, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date

October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,426 source documents archived

Query this data → isubstrate.com